Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 9/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.56 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.56 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | THPO | P40225 | 2/20 | 0.48 |
| ▸ | BLM | P54132 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18551584 | 1.00 | ESR1 (0.56) | ESR1ESR2PDCD1CD274ALDH1A1 | |
| SCHEMBL12318248 | 1.00 | ESR1 (0.56) | ESR1ESR2PDCD1CD274ALDH1A1 | |
| SCHEMBL5955203 | 0.80 | ESR1 (0.56) | ESR1ESR2PDCD1CD274ALDH1A1 | |
| SCHEMBL2669165 | 0.79 | ALDH1A1 (0.54) | ALDH1A1CYP2C9KDM4EHIF1ASMN1; SMN2 | |
| SCHEMBL14281851 | 0.78 | ESR1 (0.54) | ESR1ESR2PDCD1CD274ALDH1A1 | |
| SCHEMBL8284259 | 0.77 | ALDH1A1 (0.52) | ALDH1A1TDP1KDM4EHTR1ASMN1; SMN2 | |
| SCHEMBL8285887 | 0.77 | ALDH1A1 (0.52) | ALDH1A1TDP1KDM4EHTR1ASMN1; SMN2 | |
| SCHEMBL178538 | 0.77 | ALDH1A1 (0.52) | ALDH1A1TDP1KDM4EHTR1ASMN1; SMN2 | |
| SCHEMBL8285882 | 0.75 | ALDH1A1 (0.50) | ALDH1A1CYP2C9THPOCYP3A4ALOX15 | |
| SCHEMBL8284221 | 0.75 | ALDH1A1 (0.50) | ALDH1A1KDM4ESMN1; SMN2LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9798234-B2 | Resin composition, resist film using same, resist-coated mask blank, resist pattern forming method, and photo mask | FUJIFILM CORPORATION (JP) | 2017-10-24 | — | — | US | disclosed |
| WO-2017004077-A1 | ANTIMICROBIAL PROCHELATORS TO TARGET DRUG-RESISTANT BACTERIA AND METHODS OF MAKING AND USING THE SAME | DUKE UNIVERSITY (US) | 2017-01-05 | — | — | WO | disclosed |
| CN-104151176-B | A kind of Rivastigmine chiral intermediate and preparation method thereof | 大连韦德生化科技有限公司 | 2016-08-24 | — | — | CN | disclosed |
| CN-104151176-B | A kind of Rivastigmine chiral intermediate and preparation method thereof | 大连韦德生化科技有限公司 | 2016-08-24 | — | — | CN | disclosed |
| US-9243077-B2 | Derivative of hyaluronic acid modified with amino-carboxylic acid | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-01-26 | — | — | US | disclosed |
| US-8962642-B2 | 5-cyano-4- (pyrrolo [2,3B] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-02-24 | — | — | US | disclosed |
| US-20140045812-A1 | 5-CYANO-4- (PYRROLO [2,3B] PYRIDINE-3-YL) -PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-02-13 | — | — | US | disclosed |
| US-8530489-B2 | 5-cyano-4-(pyrrolo [2,3B] pyridine-3-yl)-pyrimidine derivatives useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-10 | — | — | US | disclosed |
| US-20120309963-A1 | 5-CYANO-4- (PYRROLO [2,3B] PYRIDINE-3-YL) -PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-06 | — | — | US | disclosed |
| US-8247421-B2 | 5-cyano-4-(pyrrolo [2,3B] pyridine-3-yl)-pyrimidine derivatives useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-21 | — | — | US | disclosed |
| US-8193183-B2 | 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin D2 receptor antagonists | AVENTIS PHARMACEUTICALS INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20100189773-A1 | 5-CYANO-4- (PYRROLO [2,3] PYRIDINE-3-YL) -PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2010-07-29 | — | — | US | disclosed |
| US-7517889-B2 | 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin D2 receptor antagonists | AVENTIS PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-7368609-B2 | Optically active 1-(fluoro-, trifluoromethyl- or trifluoromethoxy- substituted phenyl)alkylamine N-monoalkyl derivatives and process for producing same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2008-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045812-A1 | 5-CYANO-4- (PYRROLO [2,3B] PYRIDINE-3-YL) -PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | MAP3K5, CDK5, MAP4K2 | ESR1 4039/4885ESR2 4414/4885PDCD1 1322/4885 |
| US-20100189773-A1 | 5-CYANO-4- (PYRROLO [2,3] PYRIDINE-3-YL) -PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | MAP3K5, CDK5, MAP3K20 | ESR1 4011/4885ESR2 4426/4885PDCD1 1296/4885 |
| US-20120309963-A1 | 5-CYANO-4- (PYRROLO [2,3B] PYRIDINE-3-YL) -PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | MAP3K5, CDK5, MAP4K2 | ESR1 4039/4885ESR2 4414/4885PDCD1 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.